» Articles » PMID: 39045929

The Rs1862513 Promoter Variant of Resistin Gene Influences Susceptibility to Nonalcoholic Fatty Liver Disease

Overview
Specialty General Medicine
Date 2024 Jul 24
PMID 39045929
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Nonalcoholic fatty liver disease is the term used for a range of conditions in which fat builds up in the liver and exceeds 5% of hepatocytes without inordinate alcohol intake or other causes of lipid accumulation. Regarding the fact that insulin resistance and obesity play key roles in the pathogenesis of nonalcoholic fatty liver disease, as well as the connection between resistin and these metabolic diseases, the association between nonalcoholic fatty liver disease and a resistin gene (RETN) polymorphism was examined.

Methods: In this genetic case-control association study, 150 biopsy-proven nonalcoholic fatty liver disease patients and 154 controls were enrolled and genotyped for the RETN rs1862513 (-420C>G) gene polymorphism using PCR-RFLP method.

Results: The -420C>G genotype frequency distributions in both groups were consistent with Hardy-Weinberg equilibrium (HWE; p>0.05). The carriers of the RETN -420C>G "CC" genotype compared with the "GG" genotype occurred less frequently in the cases with nonalcoholic fatty liver disease than in the controls, and the difference remained significant even after adjustment for confounding factors (p=0.030; OR=0.47, 95%CI=0.36-0.93). Interestingly, the RETN -420C>G "C" allele was also associated with a decreased risk for nonalcoholic fatty liver disease too (p=0.042; OR=0.72, 95%CI=0.53-0.95).

Conclusion: We found for the first time an association between biopsy-proven nonalcoholic fatty liver disease and RETN -420C>G promoter polymorphism. The carriers of the RETN -420C>G "CC" genotype had a 53% decreased risk for nonalcoholic fatty liver disease. Our findings, however, need to be corroborated by further studies.

Citing Articles

Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease.

Fan Y, Zhang S, Wang Y, Wang H, Li H, Bai L Front Endocrinol (Lausanne). 2025; 15():1494560.

PMID: 39850476 PMC: 11754069. DOI: 10.3389/fendo.2024.1494560.

References
1.
Mahmoudi T, Nouri S, Zarei F, Najafabadi Z, Sanei M, Sayedsalehi S . Insulin-like growth factor binding protein 3 promoter variant (rs2854744) is associated with nonalcoholic fatty liver disease. Arch Endocrinol Metab. 2023; 68:e230017. PMC: 10916839. DOI: 10.20945/2359-4292-2023-0017. View

2.
Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H . HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019; 34(8):1390-1395. DOI: 10.1111/jgh.14595. View

3.
Chen W, Lu Y, Kuo S, Lin C, Tsai C, Liu S . Resistin enhances IL-1β and TNF-α expression in human osteoarthritis synovial fibroblasts by inhibiting miR-149 expression via the MEK and ERK pathways. FASEB J. 2020; 34(10):13671-13684. DOI: 10.1096/fj.202001071R. View

4.
Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H . The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004; 75(4):678-86. PMC: 1182055. DOI: 10.1086/424761. View

5.
Kamil M, Peeran S, Basheer S, Elhassan A, Alam M, Thiruneervannan M . Role of Resistin in Various Diseases with Special Emphasis on Periodontal and Periapical Inflammation - A Review. J Pharm Bioallied Sci. 2023; 15(Suppl 1):S31-S35. PMC: 10466674. DOI: 10.4103/jpbs.jpbs_655_22. View